TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
NCT01204749
Completed
The purpose of this study is to determine if treatment with paclitaxel plus AMG 386 is superior to paclitaxel plus placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/14/2016
Locations: Research Site, Phoenix, Arizona +224 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Register for Updates
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
NCT00062062
Completed
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of cancer cells and slow the growth of the tumor. Drugs used in chemotherapy such as carboplatin and paclitaxel use different ways to stop tumor cells from dividing so they stop growing or die. Combining gefitinib with carboplatin and paclitaxel may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gefitinib alone or together with carboplatin and paclitaxel works in treating older patie... Read More
Gender:
ALL
Ages:
Between 65 years and 120 years
Trial Updated:
12/12/2016
Locations: Mayo Clinic Scottsdale, Scottsdale, Arizona +140 locations
Conditions: Lung Cancer
Register for Updates
Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm
NCT01525706
Terminated
Pancreatic cysts are becoming diagnosed more frequently due to the increased use and sensitivity of imaging. A subset of these cysts are pre-cancerous, therefore suggested treatment is surgery for removal. However, surgery involves significant risks and emerging opinion suggests that not all cysts need to be surgically removed. An alternative therapy would be ideal, in particular for those where surgical risk outweighs the benefits of resection. Ethanol and paclitaxel ablation of pancreatic cyst... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
11/01/2016
Locations: St. Joseph's Health Care, London, Ontario
Conditions: Mucinous Cystic Tumor With Moderate Dysplasia, Mucinous Cystadenoma of Pancreas, Mucinous Cystadenocarcinoma of Pancreas, Benign Neoplasm of Pancreas
Register for Updates
Sealing Moderate Coronary Saphenous VEin Graft Lesions With Paclitaxel-Eluting Stents
NCT01223443
Terminated
Hypothesis: Sealing moderate SVG lesions with paclitaxel-eluting stents reduces cardiac events (death, myocardial infarction, target vessel revascularization) over the duration of follow-up. Primary objective: To evaluate the efficacy of stenting moderate SVG lesions with paclitaxel-eluting stents on reducing the first occurrence of the composite of cardiac death, myocardial infarction or repeat revascularization related to the target SVG over the duration of follow-up (minimun of 2-year follow... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2016
Locations: Institut universitaire de cardiologie et de pneumologie de Québec, Quebec, Not set
Conditions: Coronary Artery Bypass Grafting
Register for Updates
Single Agent Abraxane as Second Line Therapy in Bladder Cancer
NCT00683059
Completed
The purpose of this study is to determine what effects the drug Abraxane has on bladder cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/14/2016
Locations: Juravinski Cancer Centre, Hamilton, Ontario +4 locations
Conditions: Transitional Cell Carcinoma
Register for Updates
A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors
NCT02317419
Terminated
This is a first-in-human, open-label, multi-center, Phase 1 study of RO6927005. The study will establish the safety and tolerability profile of RO6927005 and will be conducted in two parts. In Part A, the first dose escalations will be carried out using cohorts of 1 patient. Single patient cohorts will be used to investigate increasing doses until a first dose-limiting toxicity (DLT) is reached or until grade-2 related toxicity (except infusion-related reactions), whichever comes first. At leas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2016
Locations: Not set, Bethesda, Maryland +5 locations
Conditions: Cancer
Register for Updates
Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00003299
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin, etoposide, and paclitaxel are more effective than cisplatin and etoposide alone in treating patients with extensive-stage small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin plus etoposide with or without paclitaxel in treating patien... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2016
Locations: CCOP - Scottsdale Oncology Program, Scottsdale, Arizona +19 locations
Conditions: Lung Cancer
Register for Updates
Topotecan and Paclitaxel in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer
NCT00003281
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of topotecan and paclitaxel in treating patients who have recurrent or refractory small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/12/2016
Locations: CCOP - Scottsdale Oncology Program, Scottsdale, Arizona +18 locations
Conditions: Lung Cancer
Register for Updates
Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors
NCT00072215
Terminated
RATIONALE: Drugs used in chemotherapy, such as ifosfamide, cisplatin, paclitaxel, and vinblastine, work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether ifosfamide and cisplatin are more effective when combined with paclitaxel or vinblastine in treating germ cell tumors. PURPOSE: This randomized phase III trial is studying paclitaxel, ifosfamide, and cisplatin to see how well they work compared to vinblastine, ifosfamide, and cisplatin... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
07/01/2016
Locations: Northeast Alabama Regional Medical Center, Anniston, Alabama +78 locations
Conditions: Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Register for Updates
A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer
NCT00731380
Completed
The purpose of this study is to determine the highest dose of a ABI-007 that can be given with cisplatin and 5-fluorouracil without causing intolerable side effects in patients with advanced head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2016
Locations: Princess Margaret Hospital, Toronto, Ontario
Conditions: Head and Neck Cancer
Register for Updates
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
NCT00486668
Unknown
The primary purpose of this study is to determine whether breast cancer tumors respond (as measured by pathologic complete response: the absence of microscopic evidence of invasive tumor cells in the breast) to combined chemotherapy of AC(doxorubicin and cyclophosphamide) followed by paclitaxel plus trastuzumab or lapatinib or both given before surgery to patients with HER2-positive breast cancer. Trastuzumab will also be given to all patients after surgery. The study will also evaluate the toxi... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/03/2016
Locations: MBCCOP, Gulf Coast, Mobile, Alabama +109 locations
Conditions: Invasive Breast Cancer
Register for Updates
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
NCT00686959
Completed
This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2016
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama +132 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates